For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud.
Eidos Therapeutics, Inc. (NASDAQ: EIDX) will issue 6.25 million shares between $15 and $17 Wednesday on the Nasdaq. The clinical-stage pharmaceutical is developing a Phase 2 therapy for transthyretin amyloidosis.
Aptinyx Inc. (NASDAQ: APTX) will issue more than 5.3 million shares between $14 and $16 Thursday on the Nasdaq. The spinoff of an Allergan plc (NYSE: AGN)-acquired biopharma develops therapies for neurologic disorders, including fibromyalgia and post-traumatic stress disorder.
Avrobio, Inc. (NASDAQ: AVRO) will issue more than 4.4 million shares between $16 and $18 Thursday on the Nasdaq. The gene therapy developer is advancing single-dose treatments for gaucher, pompe, cystinosis, fabry and lysosomal storage disorders.
Electrocore, LLC (NASDAQ: ECOR) will issue more than 4.3 million shares between $14 and $16 Thursday on the Nasdaq. The biotech company develops proprietary, non-invasive vagus nerve stimulation therapies to treat neurological and rheumatological conditions.
Essential Properties Realty Trust, Inc. (NYSE: EPRT) will issue 32.5 million shares between $14 and $17 Thursday on the New York Stock Exchange. The New Jersey company acquires and manages single-tenant business properties with a portfolio spanning 44 states.
I3 Verticals, Inc. (NASDAQ: IIIV) will issue nearly 6.7 million shares between $11 and $13 Thursday on the Nasdaq. The tech company provides business solutions supporting event management, loyalty programs, school operations, online payments, payment processing and rental properties.
Kezar Life Sciences, Inc. (NASDAQ: KZR) will issue nearly 4.7 million shares between $14 and $16 Thursday on the Nasdaq. The clinical-stage biotech firm develops molecular therapeutics to treat autoimmunity and cancer.
Magenta Therapeutics, Inc. (NASDAQ: MGTA) will issue nearly 6.7 million shares between $14 and $16 Thursday on the Nasdaq. Magenta is developing therapeutics to improve patient preparation, stem cell expansion, stem cell harvesting and post-transplant recovery.
Xeris Pharmaceuticals Inc (NASDAQ: XERS) will issue 5 million shares between $14 and $16 Thursday on the Nasdaq. Based in Chicago, the specialty pharmaceutical company develops and commercialize injectable therapies for hypoglycemia, congenital hyperinsulinism, acute repetitive seizures and more.
Autolus Therapeutics Ltd (NASDAQ: AUTL) will issue more than 7.8 million shares between $15 and $17 Friday on the Nasdaq. The T-cell therapy developer targets hematological cancers and solid tumors.
Dermadoctor, LLC (NASDAQ: DDOC) will issue nearly 1.9 million shares between $7 and $9 Friday on the Nasdaq. Dermadoctor develops skin care treatments for acne, eczema, rosacea and other conditions.
5 Reasons Why 2018 Could Be Good For IPO ETFs
3 Tech IPOs We Want In 2018
See more from Benzinga
- Intellia Confirms Crispr Risk Irrelevant To Its Program, With No Adjustments Needed
- Trump Approves Tariffs On About Billion Of Chinese Goods
- This Day In Market History: SEC Goes After Mafia-Linked Stock Manipulators
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.